Nucleic acid and corresponding protein entitled 101P3A41 useful in treatment and detection of cancer
View Patent ↗A novel gene (designated 101P3A11 and also referred to as PHOR-1) and its encoded protein are described. While 101P3A11 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in prostate, colon and kidney cancers. Thus, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.
1. A method to identify an agent that decreases 101P3A11 protein activity, comprising:
providing a first sample of cells and a second sample of cells, wherein the cells of each sample express 101P3A11;
contacting the first sample with a candidate compound and
measuring 101P3A11 protein activity in the first sample with the candidate compound;
measuring 101P3A11 protein activity in the second sample, wherein the second sample has not been contacted with said candidate compound;
comparing the measured 101P3A11 protein activity in said first and second samples;
whereby a diminution in the 101P3A11 protein activity in said first sample as compared to said second sample identifies said compound as an agent that decreases 101P3A11 protein activity;
wherein 101P3A11 protein is SEQ ID NO: 2866; and
wherein said activity comprises 101P3A11-mediated cAMP accumulation or a downstream signaling effect thereof which is selected from the group consisting of:
101P3A11-mediated ERK phosphorylation;
101P3A11-mediated p38 phosphorylation;
101P3A11-mediated cell growth;
101P3A11-mediated O-alpha subunit activation; and
101P3A11-mediated cell adhesion.
2. The method of claim 1 , wherein said cells have been modified to contain an expression system for said 101P3A11 protein.
3. The method of claim 1 , wherein the candidate compound is an antibody that binds specifically to the 101P3A11 protein.